Navigation Links
ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research

SAN DIEGO--(BUSINESS WIRE)--Mar 29, 2007 - ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the company will present at the 2007 International Congress on Schizophrenia Research, held from March 28 through April 1, 2007, in Colorado Springs, Colorado. Presentations will cover ACADIA's two schizophrenia programs and will include previously announced top-line clinical data from the recently completed ACP-103 Phase II schizophrenia co-therapy trial, as well as preclinical and top-line clinical data on ACP-104 for the treatment of schizophrenia.

ACP-103: Top-Line Data from Phase II Schizophrenia Co-Therapy Trial

Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA, will make an oral presentation on April 1 titled "ACP-103, a 5-HT2A Inverse Agonist in Schizophrenia and Parkinson's Disease Psychosis." This presentation will include previously announced top-line results from the recently completed ACP-103 Phase II schizophrenia co-therapy trial, which highlighted several advantages of co-therapy with ACP-103, including enhanced efficacy, a faster onset of antipsychotic action, and an improved side effect profile. Dr. Hacksell also will present new data from this study showing that patients in the co-therapy arm combining ACP-103 with risperidone (2 mg) had significantly lower prolactin levels after 42 days of treatment compared to patients in the risperidone (6 mg) plus placebo arm (p=0.0001). The condition of elevated prolactin is a commonly observed side effect of antipsychotic therapy and may adversely affect menstrual and sexual function as well as bone formation.

ACP-104: Top-Line Data From Single Ascending-Dose and Multiple Ascending-Dose Studies

Professor Carol Tamminga, M.D., from the University of Texas Sout
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Faust Pharmaceuticals Phase IIa Results for Parkinsons Disease Presented at International Congress of Parkinsons Disease and Movement Disorders
2. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
3. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
4. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
5. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
6. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
7. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
8. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
9. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
10. BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference
11. New Data Show Early Non-Response to Antipsychotic Treatment May Be Strong Predictor of Subsequent Non-Response for People with Schizophrenia
Post Your Comments:
(Date:12/22/2014)... NxStage Medical, Inc. (NASDAQ: NXTM ... announced today that the U.S. Food and Drug ... perform hemodialysis overnight while the patient is at ... System One is the first and only hemodialysis ... Home nocturnal hemodialysis is an ...
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has announced ... Market" report to their offering. ... focuses on the developments in the self-monitoring blood glucose ... Reimbursement analysis and the effects of competitive bidding have ... SMBG meters have been performed, based on the various ...
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3US Self-monitoring Blood Glucose Market 2Investment Analysis of the US Medical Device Sector 2
... ASHBURN, Va., Oct. 11, 2011 Innocoll, Inc. announces ... prevention of postoperative adhesions following abdominal and pelvic surgery. ... network of distribution partnerships. The company also plans to ... Australia, Canada, the MENA region, South East Asia, and ...
... Omeros Corporation (NASDAQ: OMER ) today announced ... Company,s Phase 3 clinical program evaluating OMS302 in intra-ocular ... products, is added to standard irrigation solution used during ... mydriasis (pupil dilation) and reduce postoperative pain and inflammation. ...
Cached Medicine Technology:Innocoll Announces European Approval for CollaGUARD®, Surgical Adhesion Barrier 2Innocoll Announces European Approval for CollaGUARD®, Surgical Adhesion Barrier 3Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302 2Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302 3
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... type 2 diabetes is dramatically increasing throughout the world. ... and it most often precedes the onset of hyperglycemia ... thiazolidinediones (TZD), the agonists of the peroxisome proliferators-activated receptor ... in the liver, adipose tissue, and skeletal muscle, thus ...
... Gordon HealthDay Reporter , MONDAY, March 14 (HealthDay ... medications for type 2 diabetes, an older drug -- metformin ... new analysis of research on diabetes medications. The ... that all of them lower blood sugar levels by a ...
... 15 (HealthDay News) -- Having a bad, short-term or poorly ... having no job, according to a new study. Researchers ... in Australia and were not surprised to find that those ... with jobs. However, the study authors also found that ...
... A nursing home industry is booming in China ... elderly population forces a nationwide shift from traditional family ... Brown University gerontologists. The study, led by Zhanlian ... in the Journal of the American Geriatrics Society ...
... If all eligible patients filled their prescriptions through a $4 ... $6 billion, according to a University of Pittsburgh Graduate School ... issue of Archives of Internal Medicine , the study ... a broad use of discounted generic medication programs that are ...
... -- The benefits of bariatric (weight loss) surgery may ... to a new scientific statement from the American Heart ... absorption of food as it passes through the ... person,s caloric intake. The statement-writing committee reviewed ...
Cached Medicine News:Health News: Metformin Still Best First-Line Type 2 Diabetes Drug 2Health News: Metformin Still Best First-Line Type 2 Diabetes Drug 3Health News:Bad Job May Be Worse for Mental Health Than No Job at All 2Health News:Nursing home boom in China has little government involvement 2Health News:Nursing home boom in China has little government involvement 3Health News:Use of $4 generic drug programs could save society billions of dollars, study shows 2Health News:Benefits of Weight-Loss Surgery May Outweigh Risks for Some, Experts Say 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: